2022-05-13T12:49:39-05:00 2021-06-30 366055558 GRANT THORNTON LLP 200 S ORANGE AVENUE SUITE 2050 ORLANDO FL 32801 990 2020-07-01 593238640 H LEE MOFFITT CANCER CENTER & RESEARCH INST LIFETIME CANCER SCREENING CTR INC HLEE 8137454673 12902 MAGNOLIA DRIVE TAMPA FL 33612 YVETTE TREMONTI EVP/CFAO 8137457862 2022-05-13 1 YVETTE TREMONTI 999009999 MICHELE N MELCHIOR P00488037 4074815100 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z MOFFITT MEDICAL GROUP G DOUGLAS LETSON 12902 MAGNOLIA DRIVE TAMPA FL 33612 113723496 0 X WWW.MOFFITT.ORG X 1994 FL TO PROMOTE AND SUPPORT H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS SUBS. 15 13 941 13 9550688 456935 3651777 1704551 101559560 111832981 0 0 746375 185964 105957712 113723496 12000 0 0 0 198771572 215083757 0 0 0 24043520 23640435 222827092 238724192 -116869380 -125000696 12167150 12286490 12601307 14836143 -434157 -2549653 X TO PROMOTE AND SUPPORT H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC (CANCER CENTER), H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL (HOSPITAL), AND H. LEE MOFFITT CANCER FOUNDATION BY EMPLOYING PHYSICIANS WHO STAFF THE HOSPITAL, BY MANAGING THEIR PRACTICE AND BY EMPLOYING THE CLINICAL SCIENTISTS WHO PROVIDE CLINICAL RESEARCH SERVICES. 0 0 213923051 102288531 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCER SCREENING CENTER, INC. ("LCS") EMPLOYS THE PHYSICIANS (KNOWN AS THE MOFFITT MEDICAL GROUP) THAT STAFF THE HOSPITAL AND PROVIDE CLINICAL RESEARCH SERVICES TO THE CANCER CENTER HEALTH CARE SYSTEM. THE PROVISION OF PRACTICE MANAGEMENT SERVICES TO ITS EMPLOYED PHYSICIANS AND CLINICAL SCIENTISTS ENHANCES THE EFFICIENCY OF HEALTHCARE AND RESEARCH SERVICES PROVIDED BY THESE EMPLOYEES. THIS BENEFITS ALL ENTITIES IN THE CANCER CENTER HEALTH CARE SYSTEM AND PROMOTES AND SUPPORTS THE RESEARCH AND ACADEMIC MISSIONS OF THE CANCER CENTER HEALTH CARE SYSTEM. 213923051 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 20 0 1 941 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 15 13 1 0 0 0 1 1 1 1 0 0 0 1 1 1 1 1 1 0 0 0 X YVETTE M LYONS TREMONTI 8137457862 12902 MAGNOLIA DR TAMPA FL 33612 X HUGO FERNANDEZ MD DIRECTOR,DEPT CHAIR MAL HEM 51.00 0.00 X 737898 0 175231 NIKHIL KHUSHALANI DIRECTOR, SR MBR HEMONCMED 51.00 0.00 X 515133 0 89349 FRANK CAPITANO DIRECTOR, CHAIR 1.00 0.00 X X 0 0 0 VICTOR YOUNG DIRECTOR, VICE CHAIR 1.00 0.00 X 0 0 0 ALLAN S MARTIN DIRECTOR, IMMED PAST CHAIR 1.00 1.00 X X 0 0 0 THE HON H LEE MOFFITT ESQ DIRECTOR, SECRETARY/TREAS 1.00 2.00 X X 0 0 0 TIMOTHY J ADAMS DIRECTOR 1.00 2.00 X X 0 0 0 JOEDRECKA BROWN SPEIGHTS MD DIRECTOR 1.00 0.00 X 0 0 0 REGINALD GOINS DIRECTOR 1.00 1.00 X 0 0 0 MARTHA TRUSLOW LANAHAN DIRECTOR 1.00 1.00 X 0 0 0 MICHAEL O'MALLEY DIRECTOR 1.00 0.00 X 0 0 0 ROBERT J PEREZ DIRECTOR 1.00 0.00 X 0 0 0 THE HON MARK A PIZZO ESQ DIRECTOR 1.00 1.00 X 0 0 0 SHARMILA SETH DIRECTOR 1.00 0.00 X 0 0 0 MARK WATSON DIRECTOR 1.00 0.00 X 0 0 0 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 8.00 50.00 X 0 1047333 362800 G DOUGLAS LETSON PRES,EVP-PIC 22.00 33.00 X 0 1011339 199081 L DAVID DE LA PARTE EVP-GEN COUNSEL;ASST SEC 8.00 50.00 X 0 927786 282255 LOUIS B HARRISON VP CHIEF PARTNERSHIPS 55.00 0.00 X 1047827 0 95099 JOANNA WEISS VP FINANCE 10.00 45.00 X 0 487230 137334 KAREN WARTENBERG VP MOFFITT MEDICAL GROUP 25.00 30.00 X 0 398126 216167 CYNTHIA TERRANO VP PAYER STRATEGIES 20.00 35.00 X 0 468352 85293 HENRY REYES VP-PARTNERSHIP DEVELOPMENT 18.00 37.00 X 0 195717 12054 ROBERT A GATENBY DEPT CHAIR DIAGNOSTIC IMAG 55.00 0.00 X 891822 0 187612 JOHN A ARRINGTON VICE CHAIR DIAGNOSTIC IMAG 55.00 0.00 X 659632 0 220860 DONALD L KLIPPENSTEIN VICE CHAIR DIAGNOSTIC IMAG 55.00 0.00 X 654882 0 156848 JULIO M POW-SANG MD DEPT CHAIR GU 50.00 0.00 X 958065 0 212472 MICHAEL A VOGELBAUM PRG LDR NEURO ONCOLOGY 50.00 0.00 X 1028793 0 79885 VERNON K SONDAK DEPT CHAIR CUTANEOUS ONC 50.00 0.00 X 823970 0 175865 JASON B FLEMING DEPT CHAIR GI TUMOR 50.00 0.00 X 897327 0 86272 LARY ROBINSON SR MBR THORCARDIO 50.00 0.00 X 947758 0 -288809 SURESH D SERAPHIN FRM VP STRAT AL TO 5/15/20 0.00 0.00 X 0 112221 242 DAVID N THRUSH FRM DEPT CHAIR ANESTHESIOLOGY 55.00 0.00 X 712534 0 236989 9875641 4648104 2722899 582 1 1 0 EMERGENCY MEDICAL ASSOCIATES OF TAMPA BA 2502 W SAINT ISABEL ST TAMPA FL 33607 OUTSOURCED CLINICAL SERVICES 1070435 LOCUMTENENS 2655 NORTHWINDS PKWY ALPHARETTA GA 30009 TEMPORARY LABOR 346934 BUCHANAN INGERSOLL & ROONEY PC 401 E JACKSON ST STE 2400 TAMPA FL 33602 LEGAL SERVICES 148304 3 1704551 1704551 NET PATIENT SERVICE REVENUE 900099 100520824 100520824 MANAGEMENT SERVICES 541610 10485438 934750 9550688 PHYSICIAN AFFILIATE FEES 900099 632754 632754 SHARED SAVINGS PROGRAM 541610 97695 97695 QUALITY IMPROVEMENT PROGRAM 541610 53687 53687 42583 42583 111832981 TAX REFUND 900099 177095 177095 INTEREST FROM INS CO 900099 8631 8631 MISC 900099 238 238 185964 113723496 102282531 9550688 185726 X 4560711 4440411 120300 740456 720925 19531 178966668 164170249 14796419 10553238 9844472 708766 10905888 10294112 611776 9356796 8467007 889789 743756 743756 39123 39123 6566117 3557764 3008353 1468117 50473 1417644 810601 65395 745206 4460945 4460945 1502592 1502592 41674 35806 5868 236658 236658 1844349 1844349 1503167 1503167 ALLOCATION OF INTERCOMP 0 8006072 -8006072 BAD DEBT EXPENSES 1808095 1808095 PROFESSIONAL DEVELOPMEN 1403689 1371664 32025 RECRUITMENT 981138 893444 87694 230414 197162 33252 238724192 213923051 24801141 0 11052155 11017645 1052895 1246445 105006 82606 33442 22400 28658 0 12167150 12286490 12601307 14836143 12601307 14836143 X -434157 -2549653 -434157 -2549653 12167150 12286490 -125000696 122885200 X X 0 1 X 1 1 1 X 680408 1728852 1749260 3651777 1704551 9514848 81144481 93818247 88234039 93262302 102282293 458741362 81824889 95547099 89983299 96914079 103986844 468256210 0 0 0 468256210 19966 7688543 301419 457935 8467863 5505 2383 746375 185964 940227 81844855 95552604 97674225 97961873 104630743 477664300 0.98030 0.98060 0.00000 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: SETTLEMENT - 2017 AMOUNT: $ 5,505. INTEREST FROM INS CO - 2018 AMOUNT: $ 2,383. 2019 AMOUNT: $ 12,931. 2020 AMOUNT: $ 8,631. HONORARIUM - 2019 AMOUNT: $ 750. MISC - 2020 AMOUNT: $ 238. TAX REFUND - 2019 AMOUNT: $ 732,694. 2020 AMOUNT: $ 177,095. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 105006 82606 22400 0 22400 PART X, LINE 2 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCER SCREENING CENTER, INC. DID NOT HAVE ANY UNCERTAIN POSITIONS IN ITS AUDITED FINANCIAL STATEMENTS, HOWEVER, THERE IS NO FOOTNOTE RELATING DIRECTLY TO UNCERTAIN TAX POSITIONS PRESENT IN THE STATEMENTS. THE ASC-740 FOOTNOTE READS AS FOLLOWS: THE CANCER CENTER RECORDS INCOME TAXES USING THE ASSET AND LIABILITY METHOD UNDER WHICH DEFERRED TAX ASSETS AND LIABILITIES ARE RECOGNIZED FOR EXPECTED FUTURE TAX CONSEQUENCES OF TEMPORARY DIFFERENCES BETWEEN FINANCIAL ACCOUNTING AND TAX BASES OF ASSETS AND LIABILITIES AND ARE MEASURED USING THE CURRENTLY ENACTED TAX RATE AND LAWS APPLICABLE IN THE PERIOD THAT THE DEFERRED TAX ASSET OR LIABILITY IS EXPECTED TO BE REALIZED OR SETTLED. 1 1 0 0 0 1 1 0 0 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 0 677014 0 244811 0 125508 0 330785 0 35379 0 1413497 0 0 G DOUGLAS LETSON PRES,EVP-PIC 0 684196 0 249005 0 78138 0 178756 0 25325 0 1215420 0 0 L DAVID DE LA PARTE EVP-GEN COUNSEL;ASST SEC 0 582568 0 212245 0 132973 0 255707 0 29911 0 1213404 0 0 JULIO M POW-SANG MD DEPT CHAIR GU 734932 0 212271 0 10862 0 183157 0 32478 0 1173700 0 0 0 LOUIS B HARRISON VP CHIEF PARTNERSHIPS 835420 0 203372 0 9035 0 74930 0 25325 0 1148082 0 0 0 MICHAEL A VOGELBAUM PRG LDR NEURO ONCOLOGY 951862 0 72022 0 4909 0 50726 0 32680 0 1112199 0 0 0 ROBERT A GATENBY DEPT CHAIR DIAGNOSTIC IMAG 735861 0 145304 0 10657 0 167835 0 23488 0 1083145 0 0 0 VERNON K SONDAK DEPT CHAIR CUTANEOUS ONC 663996 0 150939 0 9035 0 156536 0 22778 0 1003284 0 0 0 JASON B FLEMING DEPT CHAIR GI TUMOR 721654 0 170764 0 4909 0 56541 0 34349 0 988217 0 0 0 DAVID N THRUSH FRM DEPT CHAIR ANESTHESIOLOGY 611951 0 84852 0 15731 0 225220 0 15133 0 952887 0 0 0 HUGO FERNANDEZ MD DIRECTOR,DEPT CHAIR MAL HEM 620472 0 112517 0 4909 0 155455 0 23690 0 917043 0 0 0 JOHN A ARRINGTON VICE CHAIR DIAGNOSTIC IMAG 597682 0 52915 0 9035 0 198534 0 27325 0 885491 0 0 0 DONALD L KLIPPENSTEIN VICE CHAIR DIAGNOSTIC IMAG 600544 0 47929 0 6409 0 136937 0 23430 0 815249 0 0 0 LARY ROBINSON SR MBR THORCARDIO 828397 0 88354 0 31007 0 -299232 0 13470 0 661996 0 0 0 JOANNA WEISS VP FINANCE 0 328070 0 102856 0 56304 0 109791 0 37242 0 634263 0 0 KAREN WARTENBERG VP MOFFITT MEDICAL GROUP 0 265862 0 79482 0 52782 0 206394 0 12104 0 616624 0 0 NIKHIL KHUSHALANI DIRECTOR, SR MBR HEMONCMED 425756 0 83488 0 5889 0 56918 0 35693 0 607744 0 0 0 CYNTHIA TERRANO VP PAYER STRATEGIES 0 339214 0 101615 0 27523 0 70401 0 22889 0 561642 0 0 HENRY REYES VP-PARTNERSHIP DEVELOPMENT 0 178557 0 15000 0 2160 0 718 0 14006 0 210441 0 0 SURESH D SERAPHIN FRM VP STRAT AL TO 5/15/20 0 65 0 0 0 112156 0 0 0 242 0 112463 0 0 PART I, LINE 3 LCS RELIES ON H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, A RELATED ORGANIZATION WHICH USES AN INDEPENDENT COMPENSATION CONSULTANT, COMPENSATION SURVEYS OR STUDIES, AN EXECUTIVE COMPENSATION COMMITTEE, AND THE APPROVAL BY THE BOARD OR THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD, TO ESTABLISH THE PHYSICIAN IN CHIEF/PRESIDENT'S AND TOP MANAGEMENT OFFICIALS' COMPENSATION. PART I, LINES 4A-B SURESH D. SERAPHIN, FRM VP STRAT ALLIANCE & NETWK, RECEIVED SEVERENCE PAYMENTS TOTALING $112,156 DURING THE FILING YEAR. TO BE ELIGIBLE TO PARTICIPATE IN THE 457(F) NON-QUALIFIED SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (SERP), PARTICIPANTS MUST ELECT TO CONTRIBUTE AT LEAST 10% ACROSS THE 403(B) AND 457(B) PLANS, AND ARE VESTED AFTER 10 YEARS OF SERVICE. LUMP SUM DISTRIBUTIONS FROM THE ACCOUNT ARE MADE UPON NORMAL RETIREMENT OR TERMINATION. BELOW ARE INDIVIDUALS LISTED ON LCS'S 2020 FORM 990 PART VII, SECTION A, THAT PARTICIPATED IN THE 457(F) SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN AND THEIR RESPECTIVE AMOUNTS OF COMPENSATION CONSTRUCTIVELY RECEIVED IN TAX YEAR 2020 FROM THE PLAN: G. DOUGLAS LETSON - $62,690 KAREN WARTENBERG - $15,485 LOUIS D. DE LA PARTE - $48,525 YVETTE M. LYONS TREMONTI - $62,477 JOANNA WEISS - $22,652 LARY A. ROBINSON - $1,500 JULIO M. POW-SANG - $1,500 NIKHIL I. KHUSHALANI - $4,500 VERNON K. SONDAK - $1,500 LOUIS B. HARRISON - $1,500 DAVID N. THRUSH - $1,500 JOHN A. ARRINGTON - $1,500 ROBERT A. GATENBY - $1,500 DONALD L. KLIPPENSTEIN - $1,500 CYNTHIA A. TERRANO - $0 PART I, LINE 6 IN GENERAL, INCENTIVE COMPENSATION IS BASED ON MOFFITT'S ACHIEVEMENT AGAINST SPECIFIC ORGANIZATIONAL GOALS RELATED TO NET OPERATING INCOME AND ON DIVISION OR INDIVIDUAL GOALS. NET OPERATING INCOME MUST MEET OR EXCEED A CERTAIN THRESHOLD IN ORDER TO TRIGGER A PAYOUT FOR THE ORGANIZATIONAL GOAL COMPONENTS. SCHEDULE J COLUMN C THE NEGATIVE AMOUNT SHOWN FOR LARY ROBINSON IS A DECREASE IN ACTUARIAL VALUE OF THE DEFINED BENEFIT PLAN INCLUDED IN RETIREMENT AND OTHER DEFERRED COMPENSATION. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS, THAT JOINTLY SERVE ON H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCER SCREENING CENTER, INC. ("LCS") AND A FOR-PROFIT RELATED ENTITY, QUALIFY AS HAVING A BUSINESS RELATIONSHIP. LCS & MOFFITT TECHNOLOGIES CORPORATION: YVETTE LYONS TREMONTI, OFFICER LOUIS D. DE LA PARTE, OFFICER LCS & M2GEN, CORP.: TIMOTHY ADAMS, DIRECTOR ALLAN MARTIN, DIRECTOR MARTHA TRUSLOW LANAHAN, DIRECTOR LOUIS D. DE LA PARTE, OFFICER YVETTE LYONS TREMONTI, OFFICER LCS & ONCOBAY, INC.: YVETTE LYONS TREMONTI, DIRECTOR & OFFICER LOUIS D. DE LA PARTE, DIRECTOR & OFFICER TWO DIRECTORS HAVE A BUSINESS RELATIONSHIP WITH A VENDOR OF LCS'S RELATED ORGANIZATION, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. TIMOTHY J. ADAMS IS AN INVESTOR AND OWNS EQUITY IN LUMINA ANALYTICS, WHERE ALLAN S. MARTIN IS CHIEF EXECUTIVE OFFICER. JASON FLEMING AND JULIO POW-SANG ARE INDEPENDENT CONTRACTORS FOR A COMPANY, MYCAREGORITH LLC, A COMPANY FOR WHICH LOUIS HARRISON OWNS 50% OF THE SHARES. FORM 990, PART VI, SECTION A, LINE 6 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. IS THE SOLE MEMBER OF LCS. FORM 990, PART VI, SECTION A, LINE 7A AS THE SOLE MEMBER OF LCS, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. SHALL HAVE THE POWER TO APPROVE, DISAPPROVE OR REMOVE ANY MEMBER OF THE BOARD OF DIRECTORS OR OFFICER OF LCS. FORM 990, PART VI, SECTION A, LINE 7B H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (AS SOLE MEMBER) SHALL ALSO HAVE THE FOLLOWING POWERS: A. APPROVE, DISAPPROVE OR RECOMMEND THE ADOPTION, CHANGE, AMENDMENT OR REPEAL OF THE ARTICLES OF INCORPORATION OF THE CORPORATION; B. APPROVE, DISAPPROVE OR RECOMMEND THE ADOPTION, CHANGE, AMENDMENT OR REPEAL OF THE BYLAWS OF THE CORPORATION; C. APPROVE, DISAPPROVE OR RECOMMEND THE SELECTION OF A QUALIFIED AUDIT FIRM AND THE ANNUAL OPERATING AND CAPITAL BUDGETS OF THE CORPORATION; D. EITHER APPROVE OR DISAPPROVE THE TRANSFER, SALE, LEASE OR DISPOSITION OF ANY ASSET OF THE CORPORATION IN EXCESS OF TWO HUNDRED THOUSAND DOLLARS ($200,000.00); E. APPROVE OR DISAPPROVE THE CONFERRING OF ANY LIEN OR SECURITY INTEREST IN ASSETS OF THE CORPORATION IN EXCESS OF ONE MILLION DOLLARS ($1,000,000.00), WHETHER SAME SHALL BE IN CONNECTION WITH EITHER PUBLIC OR PRIVATE FINANCING, OR OTHERWISE; F. APPROVE OR DISAPPROVE ALL DONATIONS OR CHARITABLE CONTRIBUTIONS BY THE CORPORATION IN EXCESS OF TWENTY THOUSAND DOLLARS ($20,000.00) PER CONTRIBUTION OR ANNUAL CONTRIBUTION EXCEEDING FIFTY THOUSAND DOLLARS ($50,000.00) IN THE AGGREGATE; G. APPROVE, DISAPPROVE OR RECOMMEND THE ADOPTION OF THE CORPORATION'S MISSION AND PHILOSOPHY STATEMENT; H. APPROVE OR DISAPPROVE CAPITAL EXPENDITURES BY THE CORPORATION IN EXCESS OF ONE MILLION DOLLARS ($1,000,000.00) PER EXPENDITURE OR ONE MILLION DOLLARS ($1,000,000.00) IN THE AGGREGATE ANNUALLY; AND I. APPROVE, DISAPPROVE OR REMOVE ANY MEMBER OF THE BOARD OF DIRECTORS OR OFFICER OF THE CORPORATION. FORM 990, PART VI, SECTION A, LINE 8B LCS DOES NOT HAVE A COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO ELECTRONICALLY FILING FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX), A COPY OF THE RETURN IS PROVIDED TO THE GOVERNING BODY, GIVING EACH BOARD MEMBER TIME TO REVIEW THE RETURN. BOARD MEMBERS HAVE THE OPPORTUNITY TO ASK QUESTIONS RELATED TO THE INFORMATION PROVIDED ON THE RETURN. THE LCS'S FORM 990 IS ALSO PROVIDED TO THE CHIEF FINANCIAL OFFICER FOR REVIEW. BASED ON THE REVIEW ANY SUGGESTED COMMENTS OR CHANGES ARE DISCUSSED PRIOR TO SIGNING. FORM 990, PART VI, SECTION B, LINE 12C ON AN ANNUAL BASIS A PRESENTATION IS MADE TO LCS BOARD MEMBERS TO REVIEW THE CONFLICT OF INTEREST POLICY AND PROCEDURES FOR DISCLOSING ANY POTENTIAL CONFLICTS. EACH DIRECTOR, OFFICER, COMMITTEE MEMBER, AND KEY EMPLOYEE SHALL COMPLETE A CONFLICT OF INTEREST DISCLOSURE CERTIFICATION VIA THE ELECTRONIC DISCLOSURE SYSTEM. ANY DIRECTOR, OFFICER, COMMITTEE MEMBER, OR KEY EMPLOYEE WHO REASONABLY BELIEVES THAT HE OR SHE MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST MUST DISCLOSE THE EXISTENCE OF AND THE MATERIAL FACTS OF THE NATURE OF HIS/HER INTEREST ON THE FORM. THE ELECTRONIC FORM IS SUBMITTED TO THE CORPORATE COMPLIANCE OFFICE, WHICH REVIEWS THE FORMS, GATHERS ADDITIONAL RELEVANT INFORMATION WHERE NECESSARY, AND PREPARES A SUMMARY OF THE DISCLOSURES TO BE REVIEWED BY THE CONFLICT OF INTEREST WORK GROUP. IF A DIRECTOR OR COMMITTEE MEMBER DISCLOSES THAT HE/SHE HAS A POTENTIAL CONFLICT OF INTEREST AT A BOARD OR COMMITTEE MEETING, SUCH DIRECTOR OR COMMITTEE MEMBER MUST DISCLOSE THE NATURE OF THE INTEREST AND ANY RELATED INFORMATION AND RESPOND TO QUESTIONS AS MAY BE REQUIRED BY THE REMAINING MEMBERS. BASED ON THE INFORMATION DISCLOSED, THE REMAINING BOARD MEMBERS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF A CONFLICT EXISTS THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER AN ALTERNATIVE TRANSACTION OR ARRANGEMENT THAT WOULD NOT GIVE RISE TO A CONFLICT IS EQUALLY ADVANTAGEOUS. IF AN ALTERNATIVE TRANSACTION IS NOT EQUALLY ADVANTAGEOUS THE DIRECTOR OR COMMITTEE MEMBER WHO IS THE SUBJECT OF THE CONFLICT SHALL NOT VOTE ON, NOR USE HIS/HER PERSONAL INFLUENCE ON, NOR PARTICIPATE IN DISCUSSIONS OR DELIBERATIONS WITH RESPECT TO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS OF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ("MOFFITT"), A RELATED ENTITY, HAS AN ESTABLISHED SUB-COMMITTEE, THE JOINT EXECUTIVE COMPENSATION & BENEFITS COMMITTEE (JEC&BC) THAT IS MADE UP ENTIRELY OF INDEPENDENT, OUTSIDE DIRECTORS. THIS COMMITTEE IS CHARGED WITH THE OVERSIGHT OF THE PERFORMANCE AND COMPENSATION OF MOFFITT AND ITS SUBSIDIARIES' EXECUTIVES AND DISQUALIFIED PERSONS. THESE POSITIONS INCLUDE THE CEO, EXECUTIVE VICE PRESIDENTS, SENIOR VICE PRESIDENTS, VICE PRESIDENTS AND DEPARTMENT CHAIRPERSONS. TO ACCOMPLISH ITS MISSION, THE COMMITTEE CAN AS NEEDED AND DOES AT ITS DISCRETION, ENGAGE OUTSIDE INDEPENDENT, OUTSIDE ADVISORS INCLUDING, BUT NOT LIMITED TO ATTORNEYS AND COMPENSATION CONSULTANTS. ON AN ANNUAL BASIS THE JEC&BC ENGAGES A NATIONALLY KNOWN, THIRD PARTY CONSULTING FIRM TO PROVIDE A DETAILED STUDY OF THE CASH COMPENSATION FOR EACH EXECUTIVE, DISQUALIFIED PERSON AND INDIVIDUAL IN KEY POSITIONS. THE CONSULTANT USES A VARIETY OF PUBLISHED SURVEYS COMPILED BY INDEPENDENT FIRMS TO PROVIDE THE SOURCE DATA FOR THE STUDY. USING FUNCTIONALLY COMPARABLE POSITIONS IN OTHER SIMILARLY SIZED, NOT-FOR-PROFIT AND FOR-PROFIT HEALTHCARE, ACADEMIC AND RESEARCH ORGANIZATIONS, THE CONSULTING FIRM PRODUCES A STUDY THAT COMPARES EACH DESIGNATED POSITION TO ITS APPROPRIATE MARKET EQUIVALENT. THE RESULTING DATA IS PROVIDED TO THE DIRECTOR OF COMPENSATION, WHO IS NOT INCLUDED IN THE EXECUTIVE OR DISQUALIFIED PERSON CATEGORIES, FOR USE IN THE FORMULATION OF RECOMMENDATIONS FOR COMPENSATION CHANGES TO MAINTAIN MARKET COMPETITIVENESS OR TO REWARD PERFORMANCE. THESE RECOMMENDATIONS ALONG WITH THE CONSULTANT'S COMPARABILITY DATA ARE PRESENTED TO THE JEC&BC FOR IT TO CONFIRM ITS REASONABLENESS, MAKE MODIFICATIONS AS IT DEEMS NECESSARY AND PROVIDE FINAL APPROVAL. EVERY THIRD YEAR THE INDEPENDENT CONSULTANT ANALYZES THE TOTAL EXECUTIVE COMPENSATION PROGRAM, USING THE SAME METHODOLOGY AS DESCRIBED ABOVE, THAT INCLUDES THE VALUE OF ALL BENEFITS AND PERQUISITES (CASH AND NON-CASH) PROVIDED AS COMPENSATION TO THE EXECUTIVES AND DISQUALIFIED PERSONS. THE PURPOSE OF THE ANALYSIS IS TO PROVIDE AN OPINION ON THE REASONABLENESS OF EACH OF THE INDIVIDUAL COMPENSATION COMPONENTS AND THE AGGREGATE COMPENSATION TOTAL. THIS MORE COMPREHENSIVE ANALYSIS IS PROVIDED TO THE JEC&BC FOR THEIR USE IN THE ANNUAL REVIEW PROCESS. MINUTES ARE KEPT AT EACH OF THESE ANNUAL MEETINGS DETAILING THE RECOMMENDATIONS PRESENTED AND THE DECISIONS MADE BY THE COMMITTEE. THESE MINUTES ARE PUBLISHED TO THE COMMITTEE AT THE NEXT MEETING AND REPORTED BACK TO THE FULL BOARD. FORM 990, PART VI, SECTION C, LINE 19 LCS MAKES AVAILABLE ITS CONSOLIDATED AUDITED FINANCIAL STATEMENTS TO THE PUBLIC THROUGH DACBOND, A THIRD PARTY VENDORS' WEBSITES. IN ADDITION, FORM 990 IS MADE AVAILABLE ON GUIDESTAR AS WELL AS MOFFITT'S WEBSITE. ALL ORGANIZING AND GOVERNING DOCUMENTS SUCH AS FORM 1023, CONFLICTS OF INTEREST POLICY, AND BYLAWS AS WELL AS FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A, LINE 1A: EMPLOYEES WHO ARE LISTED ON MOFFITT LCS'S FORM 990 ARE EMPLOYEES WHOSE W-2'S WERE ISSUED BY MOFFITT INSTITUTE, THE COMMON PAYMASTER AND RELATED ENTITY. PROCEDURES TO REPORT COMPENSATION OF EMPLOYEES ON FORM 990 PART VII AND ON SCHEDULE J ARE IN ACCORDANCE WITH IRS INSTRUCTIONS FOR EACH RESPECTIVE SECTION. FORM 990, PART IX, COLUMN (D): THERE ARE NO FUNDRAISING EXPENSES BECAUSE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. HANDLES ALL FUNDRAISING ACTIVITIES FOR H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS SUBSIDIARIES. FORM 990, PART IX, LINE 24A: CERTAIN MOFFITT CANCER CENTER'S INTERCOMPANY OVERHEAD HAS BEEN ALLOCATED FROM THE PARENT (INSTITUTE) ENTITY TO LCS AND THOSE AMOUNTS ARE INCLUDED IN COLUMN (C) AND THEN REALLOCATED ON LINE 24A TO THE PROPER FUNCTIONAL EXPENSE CATEGORIES. FORM 990, PART XI, LINE 9: OTHER CHANGES IN NET ASSETS RELATES TO THE CLOSE OUT OF INTERCOMPANY ACCOUNTS PAYABLE AND RECEIVABLE (DUE TO/DUE FROM) IN THE AMOUNT OF $122,890,615, $-5,636 IN GRANT REFUND RECLASS AND $221 IN RECLASS OF AP. H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 PATIENT CARE FL 501(C)(3) LINE 3 H LEE MOFFITT CANCER CTR & RES INST INC 0 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 PARENT-RESEARCH FL 501(C)(3) LINE 7 N/A 0 H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE FOUNDATION INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 FUNDRAISING FL 501(C)(3) LINE 7 H LEE MOFFITT CANCER CTR & RES INST INC 0 MOFFITT TECHNOLOGIES CORPORATION 12902 MAGNOLIA DRIVE TAMPA FL 33612 300332914 TECHNOLOGY MANAGEMENT FL H LEE MOFFITT CANCER CTR & RES INST INC C 0 M2GEN CORP 10902 N MCKINLEY DRIVE TAMPA FL 33612 208486180 DATABASE MANAGEMENT FL H LEE MOFFITT CANCER CTR & RES INST INC C 0 ONCOBAY CLINICAL INC 10902 N MCKINLEY DRIVE TAMPA FL 33612 843412796 RESEARCH & PRODUCT DEVELOPMENT FL H LEE MOFFITT CANCER CTR & RES INST INC C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1